LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1
CMV Is One of the Most Common and Serious Post-transplant Infection...
Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161
Mezagitamab Had a Favorable Safety Profile, w...